Skip to main content

Reduced Dose Ibrutinib Due to Financial Toxicity in CLL

Indian Journal of Hematology and Blood Transfusion volume 35, pages 260–264 (2019)Cite this article

Abstract

Ibrutinib is the only approved novel agent that is available for the treatment of relapsed-refractory and treatment-naive chronic lymphocytic leukemia patients with deletion 17p or TP53 mutation in India. The cost of ibrutinib is still prohibitive for most Indian CLL patients. We report here for the first time dose reductions due to the patient preference of financial toxicity. We prospectively followed up patients of CLL receiving ibrutinib at a tertiary referral center in India. The period of study was from April 2016 to April 2018. Reduced dose ibrutinib was defined as a sustained (≥ 12 months) dosing at < 420 mg/day, either at treatment initiation or within 3 months from starting therapy. Progression free survival was compared using Kaplan–Meier analysis. There were a total of three patients on reduced dose and twelve patients on standard dose ibrutinib. Two patients discontinued standard dose ibrutinib due to adverse events. The patient age, cytogenetics, number of prior therapies and follow-up were not significantly different between the two groups. The rate of ≥ grade3 adverse events was significantly different between the two groups. The overall response rate and median PFS were also not significantly different between the two groups. In the limited patient numbers and follow-up period we show that outcomes of reduced dose ibrutinib are comparable to standard dose ibrutinib but with fewer adverse events. This study provides a proof of concept that a subset of patients might do well on reduced dose ibrutinib.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Fig. 1
Fig. 2

References

  1. Imbruvica® (ibrutinib) [package insert] (2017) Horsham, PA: Janssen Biotech, Inc. https://www.imbruvica.com/docs/librariesprovider7/default-document-library/prescribing_information.pdf. Accessed 5 June 2018

  2. Gayko U, Fung M, Clow F, Sun S, Faust E, Price S et al (2015) Development of the Bruton’s tyrosine kinase inhibitor ibrutinib for B cell malignancies. Ann N Y Acad Sci 1358:82–94

    Article  CAS  PubMed  Google Scholar 

  3. O’Brien SM, Furman RR, Coutre SE, Flinn IW, Burger J, Blum K, Sharman J, Wierda WG, Jones J, Zhao W, Heerema NA, Johnson AJ, Luan Y, James DF, Chu AD, Byrd JC (2016) Five-year experience with single-agent ibrutinib in patients with previously untreated and relapsed/refractory chronic lymphocytic leukemia/small lymphocytic leukemia. Blood 128:233

    Google Scholar 

  4. Ghia P, Cuneo A (2016) Ibrutinib in the real world patient: many lights and some shades. Haematologica 101(12):1448–1450

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  5. Gribben JG, Bosch F, Cymbalista F, Geisler CH, Ghia P, Hillmen P et al (2018) Optimising outcomes for patients with chronic lymphocytic leukaemia on ibrutinib therapy: European recommendations for clinical practice. Br J Haematol 180(5):666–679

    Article  PubMed  Google Scholar 

  6. Barr PM, Brown JR, Hillmen P, O’Brien S, Barrientos JC, Reddy NM et al (2017) Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL. Blood 129(19):2612–2615

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  7. Mato AR, Timlin C, Ujjani C, Skarbnik A, Howlett C, Banerjee R et al (2018) Comparable outcomes in chronic lymphocytic leukaemia (CLL) patients treated with reduced-dose ibrutinib: results from a multi-centre study. Br J Haematol 181(2):259–261

    Article  PubMed  Google Scholar 

  8. Zafar SY, Abernethy AP (2013) Financial toxicity, part I: a new name for a growing problem. Oncology (Williston Park) 27(2):80-1

    Google Scholar 

  9. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H et al (2008) Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 111(12):5446–5456

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  10. The World Bank Data. India. https://data.worldbank.org/country/india?view=chart. Accessed 10 June 10 2018

  11. Institute of Health Metrics and Evaluation. India. http://www.healthdata.org/india. Accessed 10 June 2018

  12. Global Burden of Diseases, Institute for Health Metrics and Evaluation. http://ghdx.healthdata.org/gbd-results-tool?params=gbd-api-2016-permalink/96bb6c9458e64f2f03b01dd54087438d. Accessed 6 Sept 2018

  13. Bose P, Chen L, Cruz N, Jiang Y, Wu Q, Thompson PA, Feng S, Kroll M, Jain N, Wierda W, Keating M, Gandhi V (2017) A pilot study of lower doses of ibrutinib in patients (pts) with chronic lymphocytic leukemia (CLL). Blood 130:4307

    Google Scholar 

  14. Shanafelt TD, Borah BJ, Finnes HD, Chaffee KG, Ding W, Leis JF et al (2015) Impact of ibrutinib and idelalisib on the pharmaceutical cost of treating chronic lymphocytic leukemia at the individual and societal levels. J Oncol Pract 11(3):252–258

    Article  PubMed  Google Scholar 

Download references

Author information

Affiliations

  1. Clinical Hematology, Department of Internal Medicine, Post Graduate Institute of Medical Education and Research, Chandigarh, India

    Deepesh P. Lad, Pankaj Malhotra, Alka Khadwal, Gaurav Prakash, Arihant Jain & Subhash Varma

Authors
  1. Deepesh P. Lad
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Pankaj Malhotra
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Alka Khadwal
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Gaurav Prakash
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Arihant Jain
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Subhash Varma
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Deepesh P. Lad.

Ethics declarations

Conflict of interest

The authors report no conflict of interest.

Ethical Approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional ethics committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed Consent

Informed consent was obtained from all individual participants included in the study.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Lad, D.P., Malhotra, P., Khadwal, A. et al. Reduced Dose Ibrutinib Due to Financial Toxicity in CLL. Indian J Hematol Blood Transfus 35, 260–264 (2019). https://doi.org/10.1007/s12288-018-1011-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12288-018-1011-4

Keywords

  • CLL
  • Ibrutinib
  • Reduced dose
  • Financial toxicity